Scientific Online Resource System

Annual for Hospital Pharmacy

Analysis of the cost-effectiveness of three-component therapies with daratumumab for the treatment of patients with recurrent refractory multiple myeloma

T. Vekov, H. Lebanova, N. Veleva, V. Belcheva, J. Kolev, M Vlahova


Multiple myeloma (MM) is a debilitating malignancy. It is a B-cell neoplasia affecting immunoglobulin-producing plasma cells and is the second most common hematological malignancy. The aim of the study is to model local data on long-term costs and health benefits of alternative health technologies for the treatment of patients with recurrent or refractory multiple myeloma (RRMM) and to implement an indirect comparison based on network meta-analysis. Data on future health benefits and costs after the end of the POLLUX and CASTOR clinical trials were modeled using a Markov model with two health states and one absorbing state. The model includes all possible health states that reflect the course of the disease and provides all the probabilities of transition from one health state to another. Input data in the model are the primary and secondary endpoints in randomized multicenter trials identified and measured as progression-free survival, time to disease progression, very good partial response, minimal residual disease, overall survival, and response duration. The time horizon of the model is lifelong. Costs and benefits are discounted at 3.5% per annum. The chosen perspective is the point of view of the third party payer. The modeling was performed using the Tree Age Pro Healthcare software product. A cost-effectiveness analysis and indirect comparison was performed based on a network meta-analysis of alternative health technologies designed to treat patients with RRMM. The incremental ratio of additional costs and additional health benefits for the studied alternative therapies were calculated. Deterministic and probabilistic sensitivity analysis were used to assess safety. The results show that the three-component therapy daratumumab/lenalidomide/dexamethasone is not a cost-effective therapy compared to lenalidomide/dexamethasone and daratumumab/bortezomib/dexamethasone for the treatment of patients with RRMM due to the high cost of a therapeutic course. The value of the cost-benefit ratio of daratumumab/lenalidomide/dexamethasone compared to therapeutic alternatives significantly exceeds the cost-effectiveness threshold, which is ICER ≤ BGN 50,000/QALY. In order to reach the cost-effectiveness threshold, the marketing authorization holder of daratumumab needs to reduce its price by at least 6.25% in the negotiation process with the payer.


recurrent or refractory multiple myeloma, therapy, cost-effectiveness analysis

Full Text


Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009 Jul 25;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X.

Castillo JJ. Plasma Cell Disorders. Prim Care. 2016 Dec;43(4):677-691. doi: 10.1016/j.pop.2016.07.002.

Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242.

Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.

Национална болница по онкология. Български национален раков регистър. vol. 25, 2017.

Abdallah N, Kumar SK. Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol. 2019 Dec 23;10:2040620719894871. doi: 10.1177/2040620719894871.

Perincheri S, Torres R, Tormey CA, et al. Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma. Blood, 2016, 128 (22): 5630, doi:

Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30. doi: 10.1053/j.seminoncol.2005.06.018.

Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x.

Gelman JS, Sironi J, Berezniuk I, et al. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One. 2013;8(1):e53263. doi: 10.1371/journal.pone.0053263.

Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859-88. doi: 10.2165/00003495-200969070-00006.

Grigorov EE, Vaseva VS, Getov IN. Applied pharmacoeconomics – methodology, structuring and conducting of pharmacoeconomical studies, Journal of International Scientific Publications: Economy & Business. 2013;7(1):540-551. doi:

Garber AM, Phelps CE. Economic foundations of costeffectiveness analysis. J Health Econ. 1997 Feb;16(1):1-31. doi: 10.1016/s0167-6296(96)00506-1.

Mateos MV, Spencer A, Nooka AK, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age:

subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448.

Weisel K, Spencer A, Lentzsch S, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020 Aug 20;13(1):115. doi: 10.1186/s13045-020-00948-5.

European Network for Health Technology Assessment, Guideline, Comparators and Comparisons, Criteria for the choice of the most appropriate comparators, Summary of current policies and best practice recommendations, Adapted version, 2015.

Shtereva D. Types of methods of economic evaluations in the healthcare sector. Journal of International Scientific Publications: Economy & Business, 2010;4(4):4-11.

Zhang TT, Wang S, Wan N, et al. Cost-effectiveness of Daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. Clin Ther. 2018 Jul;40(7):1122-1139. doi: 10.1016/j.clinthera.2018.05.012.

Zeng X, Peng L, Peng Y, et al. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. Clin Ther. 2020 Feb;42(2):251-262. e5. doi: 10.1016/j.clinthera.2019.12.007.

Paquete A, Gouveia M, Guerreiro R. et al. PCN67 Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal. ISPOR Europe 2019, 2-6 November 2019, Copenhagen, Denmark. Abrstarct in: Value in Health, 2019 Nov, 22(S3): S448.



Article Tools
Email this article (Login required)